Icagen & Pfizer Enter Research Pact With Yale

A three-party collaboration deal has been achieved among the Yale School of Medicine, Pfizer, Inc. and Icagen, Inc. to investigate potential new pain compounds.

Icagen and Pfizer have inked a collaboration agreement with the Yale School of Medicine to investigate potential new pain compounds identified by Icagen and Pfizer in their existing collaboration.

P. Kay Wagoner, Ph.D., chief executive officer of Icagen, said, “We are very pleased that Yale researchers Stephen Waxman, M.D. and Sulayman Dib-Hajj M.D. have agreed to work with us and our partner Pfizer in the study of Nav1.7 channels from inherited erythromelalgia (IEM) patients. Drs. Waxman and Dib-Hajj are among the world’s leading researchers in the role of sodium channels in pain. The studies we are jointly undertaking should help us better understand how modulating Nav1.7 channels in IEM patients may reduce the extreme pain experienced by these patients. This information may additionally assist our broader efforts to find novel sodium channel treatments f